CDH1 and cancer: Consistent with the results observed in tumor relapses, Met-M samples slightly reduced the percentage of Ecad+ cancer cells (Fig. 4I) and were enriched in Vim+ (Fig. 4J) and ITGAV+ (Fig. 4K) cancer cells compared with Met-PT samples, with both conditions showing a similar percentage of ITGAV+Vim+ cancer cells (Fig. 4L).